Engineering β-cell islets or islet-like structures for type 1 diabetes treatment.

Area of Science:

• Biomedical Engineering
• Immunology
• Endocrinology

Background:

• Type 1 diabetes mellitus results from pancreatic beta-cell destruction, necessitating insulin therapy with limitations in glycemic control.
• Current treatments like insulin injections lack physiological regulation.
• Islet transplantation faces challenges due to donor scarcity and immune rejection.

Purpose of the Study:

• To explore bioengineering strategies for improving beta-cell therapy in type 1 diabetes.
• To investigate islet encapsulation for immunoisolation and immunomodulation.
• To enhance the viability and function of transplanted beta-cells.

Main Methods:

• Utilizing semi-permeable coatings made of biocompatible materials for islet encapsulation.
• Integrating immunomodulatory approaches, including co-transplantation with mesenchymal stem cells (MSCs).
• Engineering beta-cell islets or microtissues with enhanced vascularization.

Main Results:

• Encapsulation provides physical protection against immune attacks and allows for local delivery of immune-regulatory factors.
• Mesenchymal stem cells (MSCs) demonstrate immunomodulatory properties, controlling graft inflammation.
• Growth factors like IL-10 and LIF contribute to immune regulation.

Conclusions:

• Combining immunoisolation and immunomodulation via beta-cell encapsulation is a promising strategy for type 1 diabetes.
• Engineered beta-cell microtissues can improve transplanted cell function and survival.
• Promoting vascular network formation is crucial for long-term graft success.